The peripheral dose (PD) is defined as the dose delivered to tissues outside the collimated radiotherapy beam. This absorbed dose will be of clinical concern if any uninvolved radiosensitive or critical structures outside the beam were to receive dosages approaching their tolerance levels. Sources of the PD include head leakage (transmission through the collimation system), collimator scatter, scatter and secondary particle production from a beam modifier (tissue compensator, wedge filter or shielding) present in the beam and scatter arising from within tissue. A fifth source, that due to radioactivity induced within the patient by a high-energy beam, is not considered in this work. In the past, several studies have been undertaken to characterize the peripheral dose as a function of beam modality and quality, field dimension, the separation between the radiation source and the patient and the presence and composition of a beam modifier (Keller et al, 1974; Scrimger & Kolitsi, 1979; Nusslin & Hassenstein, 1980; Fraass & van de Geijn, 1983; Greene et al, 1983; Kase et al, 1983; Starkschall et al, 1983; Greene et al, 1985; Sherazi & Kase, 1985; Francois et al, 1988). Peripheral doses at specific clinical sites, such as the contralateral breast (Fraass et al, 1985) and the gonads (Yau et al, 1981), have also been measured on patients and within anthropomorphic phantoms. In general, these studies indicate that the PD decreases approximately exponentially with distance from the beam edge.
Read full abstract